211 related articles for article (PubMed ID: 19372579)
1. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.
Zhang Y; Zhao H; Asztalos S; Chisamore M; Sitabkhan Y; Tonetti DA
Mol Cancer Res; 2009 Apr; 7(4):498-510. PubMed ID: 19372579
[TBL] [Abstract][Full Text] [Related]
2. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
3. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
Murphy CS; Pink JJ; Jordan VC
Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
[TBL] [Abstract][Full Text] [Related]
6. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.
Molloy ME; White BE; Gherezghiher T; Michalsen BT; Xiong R; Patel H; Zhao H; Maximov PY; Jordan VC; Thatcher GR; Tonetti DA
Mol Cancer Ther; 2014 Nov; 13(11):2515-26. PubMed ID: 25205655
[TBL] [Abstract][Full Text] [Related]
7. Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.
Rose-Hellekant TA; Skildum AJ; Zhdankin O; Greene AL; Regal RR; Kundel KD; Kundel DW
Cancer Prev Res (Phila); 2009 May; 2(5):496-502. PubMed ID: 19401525
[TBL] [Abstract][Full Text] [Related]
8. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
[TBL] [Abstract][Full Text] [Related]
10. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
Riggio M; Polo ML; Blaustein M; Colman-Lerner A; Lüthy I; Lanari C; Novaro V
Carcinogenesis; 2012 Mar; 33(3):509-18. PubMed ID: 22180571
[TBL] [Abstract][Full Text] [Related]
12. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines.
Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R
Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611
[TBL] [Abstract][Full Text] [Related]
13. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
14. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions.
Pontiggia O; Rodriguez V; Fabris V; Raffo D; Bumaschny V; Fiszman G; de Kier Joffé EB; Simian M
Breast Cancer Res Treat; 2009 Jul; 116(2):247-55. PubMed ID: 18622696
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation.
Fan M; Nakshatri H; Nephew KP
Mol Endocrinol; 2004 Nov; 18(11):2603-15. PubMed ID: 15284335
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
Montecchia MF; Lamb C; Molinolo AA; Luthy IA; Pazos P; Charreau E; Vanzulli S; Lanari C
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):11-21. PubMed ID: 10215033
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Lau KM; LaSpina M; Long J; Ho SM
Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
[TBL] [Abstract][Full Text] [Related]
18. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models.
Bhat KP; Lantvit D; Christov K; Mehta RG; Moon RC; Pezzuto JM
Cancer Res; 2001 Oct; 61(20):7456-63. PubMed ID: 11606380
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
20. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
